ProCE Banner Activity

Navigating the Complex Treatment Landscape in Relapsed/Refractory Myeloma

Multimedia

In this on-demand webcast from a live webinar, Paul G. Richardson, MD; Natalie S. Callander, MD; and Noopur Raje, MD, discuss recent advances in new and emerging therapies for patients with relapsed/refractory multiple myeloma.

Released: October 12, 2022

Expiration: October 11, 2023

Share

Faculty

Paul G. Richardson

Paul G. Richardson, MD

Associate Professor of Medicine
Harvard Medical School
Clinical Director
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Natalie S. Callander

Natalie S. Callander, MD

Professor of Medicine
School of Medicine and Public Health
University of Wisconsin
Director, Myeloma Clinical Program
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

Noopur Raje

Noopur Raje, MD

Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Provided by

Provided by Medical Learning Institute, Inc. in partnership with Clinical Care Options, LLC.
ProCE Banner

Supporters

Supported by educational grants from

Janssen administered by Scientific Affairs

Karyopharm Therapeutics Inc

Regeneron Pharmaceuticals, Inc.

Target Audience

This educational program is intended for hematologists, medical oncologists, nurses, pharmacists, and other healthcare professionals who treat patients with R/R MM

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Plan therapeutic strategies for patients with R/R MM based on currently available data, individual patient and disease characteristics, and response to and tolerance of prior therapy
  • Evaluate the efficacy and safety evidence of novel combination therapeutic regimens for patients with R/R MM
  • Mitigate treatment-related symptoms associated with new targeted therapies in patients with R/R MM
  • Identify patients with R/R MM who would be eligible for enrollment on clinical trials

Program Director Disclosure

Program Director

Paul G. Richardson, MD

Associate Professor of Medicine
Harvard Medical School
Clinical Director
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Paul G. Richardson, MD: consultant/advisor/speaker: AstraZeneca, Celgene/Bristol Myers Squibb, GlaxoSmithKline, Karyopharm, Novartis, Oncopeptides, Sanofi, Secura Bio, Takeda; researcher: Celgene/Bristol Myers Squibb, Karyopharm, Oncopeptides, Takeda.

Faculty Disclosure

Primary Author

Natalie S. Callander, MD

Professor of Medicine
School of Medicine and Public Health
University of Wisconsin
Director, Myeloma Clinical Program
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

Natalie S. Callander, MD, has no relevant financial relationships to disclose.

Noopur Raje, MD

Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Noopur Raje, MD: consultant/advisor/speaker: AbbVie, Amgen, Bluebird Bio, Bristol-Myers Squibb, Caribou Biosciences & Immuneel, Janssen, Pfizer, Sanofi, Takeda; researcher: Bluebird Bio.

Staff Disclosure

Staff

Terrence Fagan,

Associate Scientific Director

Terrence Fagan has no relevant financial relationships to disclose.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant financial relationships to disclose.

Ramya Moorthy,

Clinical Editor

Ramya Moorthy, has no relevant financial relationships to disclose.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant financial relationships to disclose.

Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant financial relationships to disclose.

Brian Purves, PharmD, MBA

Brian Purves, PharmD: The following relationships have ended within the last 24 months: Employee of AstraZeneca with focus in Medical Information for Respiratory Inhaled-Symbicort.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant financial relationships to disclose.

Kristen Rosenthal, PhD

Clinical Editor

Kristen M. Rosenthal, PhD, has no relevant financial relationships to disclose.

Terran W. Sims, MSN, ACNP-C, CNN-BC, COCN

Nurse Practitioner
Department of Urology
University of Virginia
Charlottesville, Virginia

Justine Stanley, MSc

Editorial Contributor

Justine Stanley, MSc, has no relevant financial relationships to disclose.

Saranya Vijayakumar, PhD

Clinical Editor

Saranya Vijayakumar, PhD, has no relevant financial relationships to disclose.

Instructions for Credit

Joint Accreditation Statement

Physician Continuing Medical Education

Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 12, 2022, through October 11, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70.00% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge and competence of learners in selecting individualized treatments for patients with R/R MM.